Saturday, April 13, 2019 5:48:52 AM
They only listed one author per paper, he is referenced (et al) in this one at least. I recognize the paper, could be others.
Velasco-Velazquez, M. et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72, 3839–3850 (2012).
http://cancerres.aacrjournals.org/content/72/15/3839
I think negotiations are still ongoing, but we have reached a point without a finalized deal, they need to start looking at a backup plan. My guess on the TNBC delay, legalistically issues starting the trial, including getting all 5 sites onboard. If you look at any other trial, just for example with the pi alone, it usually takes several months to start.
My opinion also, but the TNBC trial is a high priority, second only to finishing the BLA and they start it soon, the 10Q was updated to starting Q2. It is a small trial, costing a few million, not the 25 million the mono trial has costed. Good early results should pay massive dividends giving them much larger leverage in negotiations, nee potential partners, etc.
I agree on the money. It is frustrating knowing that is really the main item holding this stock back. They have been chipping away at it though, each month, the amount needed until approval gets smaller, eventually we will break free.
Also, we are due an update, especially with TNBC trial. I’m assuming they have leveraged that info for the latest offering as usual, but I’m tired of speculating now for three months and feel all shareholders deserve a full update, be it good or bad.
Velasco-Velazquez, M. et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72, 3839–3850 (2012).
http://cancerres.aacrjournals.org/content/72/15/3839
I think negotiations are still ongoing, but we have reached a point without a finalized deal, they need to start looking at a backup plan. My guess on the TNBC delay, legalistically issues starting the trial, including getting all 5 sites onboard. If you look at any other trial, just for example with the pi alone, it usually takes several months to start.
My opinion also, but the TNBC trial is a high priority, second only to finishing the BLA and they start it soon, the 10Q was updated to starting Q2. It is a small trial, costing a few million, not the 25 million the mono trial has costed. Good early results should pay massive dividends giving them much larger leverage in negotiations, nee potential partners, etc.
I agree on the money. It is frustrating knowing that is really the main item holding this stock back. They have been chipping away at it though, each month, the amount needed until approval gets smaller, eventually we will break free.
Also, we are due an update, especially with TNBC trial. I’m assuming they have leveraged that info for the latest offering as usual, but I’m tired of speculating now for three months and feel all shareholders deserve a full update, be it good or bad.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
